Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
February 2013, Vol 4, No 2
February 2013, Vol 4, No 2
New Approach to Treatment Resistance in Head and Neck Cancers
Value Propositions
,
Value Peer-spectives
February 2013, Vol 4, No 2
The majority of head and neck tumors are associated with a deregulation of the PI3K/AKT/mTOR pathway, which has until now been seen as the culprit in treatment resistance in these cancers.
Read Article
HHS Allocates $1.9 Million to Establish Telehealth Programs for Underserved Populations
Value Propositions
,
Value Peer-spectives
February 2013, Vol 4, No 2
The HHS has allocated $1.9 million for new telehealth regional resource centers to serve rural and medically underserved populations.
Read Article
AACR Is Launching Cancer Immunology Research Journal
Value Propositions
,
Value Peer-spectives
February 2013, Vol 4, No 2
The American Association for Cancer Research (AACR) has announced the launch of its newest online journal, Cancer Immunology Research, in the spring at the AACR 2013 annual meeting.
Read Article
Starr Cancer Consortium Awards $5 Million to 5 Research Teams to Advance Patient Care
Value Propositions
,
Value Peer-spectives
February 2013, Vol 4, No 2
The Starr Foundation’s sixth Starr Cancer Consortium (SCC) Grant Competition awarded $5 million to 5 cancer research teams focusing on discovering new cancer mechanisms related to genetic mutations or epigenetic involvement in a variety of cancers.
Read Article
New Medicare Rules Will Save Providers $676 Million Annually
Value Propositions
,
Value Peer-spectives
February 2013, Vol 4, No 2
Removing Medicare regulations that are deemed unnecessary or unjustifiably burdensome on providers and hospitals would save nearly $676 million annually, and $3.4 billion over 5 years, through a rule proposed by the Centers for Medicare & Medicaid Services (CMS) in support of President Obama’s call on federal agencies to modify and streamline regulations on business.
Read Article
FDA Expedites Approval of Generic Version of Doxil
FDA Approvals, News & Updates
February 2013, Vol 4, No 2
Drug shortages have hit the oncology community hard. Determined to alleviate the much-publicized drug shortage associated with doxorubicin hydrochloride liposome injection (Doxil; Janssen), the FDA expedited the approval of the first generic version of this agent, which is produced by Sun Pharma Global FZE (Sun).
Read Article
Cost-Effectiveness of MRI Screening in Women with Familial Breast Cancer Risk
Economics & Value
,
Health Economics
February 2013, Vol 4, No 2
San Antonio, TX—Adding magnetic resonance imaging (MRI) to a breast cancer screening strategy for women with a familial risk of cancer costs approximately 2.6 times as much per life-years gained compared with screening with mammography alone, Dutch researchers reported at the CTRC-AACR San Antonio Breast Cancer Symposium.
Read Article
Exploring Men’s Willingness to Pay for Prostate Cancer Screening to Avoid Unnecessary Biopsy and Treatment
By
Rosemary Frei, MSc
Prostate Cancer
February 2013, Vol 4, No 2
>Dutch researchers have peered into the minds and wallets of a group of men aged 55 to 75 years to determine what they are willing to trade for a reduced risk of prostate cancer–related death or to avoid unnecessary procedures and treatment.
Read Article
Nab-Paclitaxel Added to Gemcitabine Extends Survival in Patients with Metastatic Pancreatic Cancer
By
Mark Knight
GI Cancers Symposium
February 2013, Vol 4, No 2
When added to gemcitabine, weekly
nab
-paclitaxel improved survival in patients with advanced pancreatic cancer by nearly 2 months compared with gemcitabine alone, said Daniel D. Von Hoff, MD, FACP, Physician in Chief and Director of Translational Research, Translational Genomics Research Institute, Phoenix, regarding the results of a large international phase 3 clinical trial.
Read Article
Infection Poses Lethal Risk Early in Patients with Multiple Myeloma
By
Charles Bankhead
ASH 2013 Annual Meeting
February 2013, Vol 4, No 2
Atlanta, GA—Many patients with multiple myeloma succumb to infection before they have a chance to benefit from cancer therapy, according to a new study from Sweden.
Read Article
Page 3 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma